newsfilter
← Latest News
GlobeNewswire·

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Vancouver, Canada, June 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel,